Targeted treatment of mature T-cell lymphoma

A method of treating a patient suffering from aggressive peripheral T-cell lymphoma (PTCL), comprising administering to a PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma (ALCL), or angioimmunoblastic T-cell lymphoma (AITL) patient in need of treatment an effective amount of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide, or a pharmaceutically acceptable salt or hydrate thereof,

• wherein the administering comprises:
• administering a loading dose of 75 mg/dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof two or three times per week for at least one week of a 28 day cycle;
• followed by
• administering a maintenance dose of 50 mg/dose of 4,4,4-trifluoro-N-[(1S)-2-[[(7S)-5-(2-hydroxyethyl)-6-oxo-7H-pyrido[2,3-d] [3]benzazepin-7-yl]amino]-1-methyl-2-oxo-ethyl]butanamide or a pharmaceutically acceptable salt or hydrate thereof three times per week.